Patient satisfaction and safety of Atezolizumab in routine care
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This study tracks how well Atezolizumab (Tecentriq) works for people with certain lung or liver cancers in everyday medical practice. It helps doctors understand if patients are satisfied with their treatment and how it affects their quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancers: non-small cell lung cancer (NSCLC), small cell lung cancer that has spread widely (ES-SCLC), or advanced liver cancer that cannot be removed by surgery.
- If you have NSCLC, your tumor must have a high level of PD-L1 (a protein that helps the immune system fight cancer).
- You do not have certain gene changes (EGFR mutation or ALK rearrangement) if you have NSCLC.
- You have not already received more than 4 doses of Atezolizumab.
- You are not currently taking other cancer drugs along with Atezolizumab.
- You are willing to complete short surveys about how you feel and your treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a combination of immune therapy (atezolizumab) and a blood-vessel-targeting drug (bevacizumab) works better than a standard procedure called TACE for people with intermediate-stage liver cancer (HCC). It may help shrink tumors and help patients live longer with fewer complications.
This study tests whether adjusting the dose of the immunotherapy drug atezolizumab (Tecentriq) based on its levels in your blood works well. You may be able to join if you have advanced cancer and your doctor already plans to give you this drug (alone or with other approved treatments).
This trial tests if the immunotherapy drug atezolizumab can prevent early stage non-small cell lung cancer from coming back after surgery. It is for people whose tumors have high levels of a protein called PD-L1 (50% or more) and do not have certain gene changes (EGFR or ALK).
This trial looks at how well atezolizumab works for people with stage IV non-small cell lung cancer that has a high level of PD-L1 (a protein that helps cancer hide from the immune system). It's for people getting atezolizumab as their first treatment.
This Phase 2 study tests whether atezolizumab combined with a multi-targeted (“multi-kinase”) inhibitor can treat advanced liver cancer that cannot be cured with surgery or local procedures. It focuses on people whose cancer has already grown despite a first-line treatment using atezolizumab plus bevacizumab.
This Phase 2 study tests atezolizumab, an immunotherapy drug, in people with advanced, incurable solid tumors whose tumor DNA/RNA suggests they may respond. The goal is to see if the treatment works better for patients selected by these lab results.
Hear when a new Lung Cancer, Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.